RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage

BACKGROUND: Paclitaxel (PTX), a first-line therapy for triple negative breast cancers (TNBC) induces anti-tumor activity by microtubule stabilization and inhibition of cell division. Its dose-limiting toxicity and short half-life, however, pose clinical challenges underscoring the need for strategie...

Descripción completa

Detalles Bibliográficos
Autores principales: Haynes, Brittany M., Cunningham, Kristen, Shekhar, Malathy P. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578210/
https://www.ncbi.nlm.nih.gov/pubmed/36258187
http://dx.doi.org/10.1186/s12885-022-10119-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578210/
https://www.ncbi.nlm.nih.gov/pubmed/36258187
http://dx.doi.org/10.1186/s12885-022-10119-z

Ejemplares similares